Caraway Therapeutics

Please note: The information displayed on this page might be outdated.
Caraway Therapeutics: Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically-defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. Caraway is a leader in targeting mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Pre-Clinical Stage
Listing
Private
Therapeutic Modalities
Small Molecule
Website:
Address:
Cambridge, MA
United States

Company Participants at Fall Private Company Showcase 2022

  • Martin D. Williams, CEO

Upcoming Company Event Participation